These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23731475)

  • 1. Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis.
    Koga M; Terawaki S; Tatsukawa R; Fujita M; Imafuku S; Nakayama J
    J Dermatol; 2013 Jun; 40(6):476-7. PubMed ID: 23731475
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
    Marcella S; Welsh B; Foley P
    Australas J Dermatol; 2011 Aug; 52(3):e8-11. PubMed ID: 21834808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
    Imafuku S; Tatsukawa R; Ito K; Nakayama J
    J Dermatol; 2012 Dec; 39(12):1070. PubMed ID: 22698067
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor necrosis factor inhibition and glucose homeostasis.
    Larsen AJ; Clarke JT
    J Am Acad Dermatol; 2013 Jun; 68(6):e182-3. PubMed ID: 23680212
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycobacterium marinum infection in a case of psoriasis treated with antitumor necrosis factor α antibody detected by QuantiFERON(®) -TB test.
    Kaneko S; Seishima M; Asano Y; Chinuki Y; Morita E
    Int J Dermatol; 2014 Mar; 53(3):e187-9. PubMed ID: 23675972
    [No Abstract]   [Full Text] [Related]  

  • 6. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
    Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
    Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 8. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy.
    Hay RA; Pan JY
    Clin Exp Dermatol; 2014 Aug; 39(6):751-2. PubMed ID: 24984757
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term psoriasis treatment].
    Jullien D; Battistella M
    Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
    [No Abstract]   [Full Text] [Related]  

  • 10. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cat-scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of the literature.
    Osório F; Pedrosa A; Azevedo F; Figueiredo P; Magina S
    Int J Dermatol; 2014 Mar; 53(3):e182-3. PubMed ID: 23557494
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis.
    Kimura U; Kinoshita A; Sekigawa I; Takamori K; Suga Y
    J Dermatol; 2012 Dec; 39(12):1071-2. PubMed ID: 22506677
    [No Abstract]   [Full Text] [Related]  

  • 13. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
    Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
    J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Miliary tuberculosis following treatment with adalimumab].
    Lertxundi U; Mayo J; García M; Ruiz B; Aguirre C
    Farm Hosp; 2005; 29(5):344-6. PubMed ID: 16351458
    [No Abstract]   [Full Text] [Related]  

  • 18. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.